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Abstract
Background: Ethnic and socioeconomic inequities in use of breast cancer adjuvant therapy are well documented
in many countries including the USA, and are known to contribute to lower breast cancer survival among minority
ethnic and socioeconomically deprived women. We investigated ethnic and socioeconomic inequities in use of
adjuvant radiotherapy and chemotherapy in a cohort of women with invasive breast cancer in New Zealand.
Methods: All women with newly diagnosed invasive breast cancer during 1999-2012 were identified from the
Waikato Breast Cancer Register. Rates of chemotherapy use and radiotherapy use were assessed in women who
were deemed to be eligible for chemotherapy (n = 1212) and radiotherapy (n = 1708) based on guidelines. Factors
associated with use of chemotherapy and radiation therapy were analysed in univariate and multivariate regression
models, adjusting for covariates.
Results: Overall, rates of chemotherapy and radiotherapy use were 69% (n = 836) and 87.3% (n = 1491), respectively.
In the multivariate model, significantly lower rates of radiotherapy use were associated with Māori compared with
NZ European (Odds Ratio [OR] = 0.63, 0.40-0.98), presence of comorbidity (OR = 0.49, 0.34-0.72), distance from
hospital of over 100km (OR = 0.47, 0.23-0.96), mastectomy compared with breast conserving surgery (OR = 0.32, 0.
17-0.56) and non-screen compared with screen detection (OR = 0.53, 0.35-0.79). No significant associations were
observed between chemotherapy use and ethnic or socio-demographic factors.
Conclusions: Improving access for radiotherapy, especially for women who are at a higher risk of not receiving
optimum cancer therapy due to ethnicity, geography or socioeconomic status need to be recognized as a priority
to reduce inequities in breast cancer care in New Zealand.
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Background
Disparities in breast cancer survival by ethnicity and
socioeconomic status are well documented in many
countries [1–4]. As in the USA, poor healthcare access
among ethnic minority or Indigenous and socioeconom-
ically deprived women has been shown to be a major
factor for such breast cancer survival disparities [2].
Differences in quality and timeliness in treatment of
breast cancer, including differences in the use of adju-
vant therapy have also been reported to be important
contributors for ethnic and socioeconomic disparities in
breast cancer survival [1, 5, 6].
Indigenous Māori in New Zealand are known to have
lower access, receive inferior quality cancer care and
experience longer cancer treatment delays compared
with non-Indigenous NZ Europeans for a variety of
cancers [7–10]. For instance, Māori patients have been
reported to experience longer delays for surgical treat-
ment of breast and lung cancer, and to have a lower
likelihood of receiving chemotherapy for bowel cancer
compared with NZ European patients [7, 8]. Breast
cancer mortality rate in Māori is 60% higher compared
with NZ European women, and more advanced cancer
stage at diagnosis in Māori has been shown to be the
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major factor towards this disparity [11]. However, data
are sparse on possible ethnic differences in use, quality
or timeliness of adjuvant therapy for breast cancer in
New Zealand.
New Zealanders receive healthcare through a mix-
ture of public and privately-funded services. Publicly
funded health service is well resourced and provides
free specialist and hospital care to all citizens. Private
health care facilities run parallel to the public and are
mostly funded through insurance schemes. BreastSc-
reen Aotearoa (BSA) is the national breast cancer
screening programme which provides free biennial
breast cancer screening for all women aged 45-69
years. The Waikato District Health Board region has a
population of just over 400,000. It has a major urban
centre, a significant rural population and a Māori
population of nearly 84,000 [12]. While a majority of
women receive surgical care through the public sector
a minority receive surgical care through well-equipped
private sector hospitals. Oncology services for the re-
gion are available only through the public sector. Radi-
ation facilities for the region are provided exclusively
through the radiation facility at the tertiary hospital in
Hamilton. A majority receive chemotherapy through
the same tertiary centre in Hamilton while a minority
receive chemotherapy through a satellite facility.
We hypothesized that Māori women were less likely
to have received recommended adjuvant chemother-
apy and/or radiotherapy compared with NZ European
women [13, 14], which might have contributed to the
higher breast cancer mortality in Māori women. To
answer this question, we analysed cancer treatment data
from a regional, population based sample of women with
newly diagnosed breast cancer over a period of 14 years.
Rates of adjuvant chemotherapy and radiotherapy use by
socio-demographic and tumour characteristics were ana-
lysed individually, and adjusting for covariates, to identify




Data for this study were extracted from the Waikato
Breast Cancer Register (WBCR), a prospective database
of newly diagnosed breast cancers in the Waikato, New
Zealand since 1999. Completeness and accuracy of the
WBCR data have been validated previously [15]. All
women with newly diagnosed primary invasive breast
cancer during the period from 01/01/1999 through 31/12/
2012, were identified from the WBCR (n = 2848). Of this,
women with metastatic cancer at diagnosis (n = 166) and
women who did not undergo primary surgery (n = 114)
were excluded.
Data
Patient ethnicity was obtained from the WBCR which
records self-assigned ethnicity and was grouped into four
categories; Māori, Pacific, NZ European, and Other. Cancer
staging was performed according to TNM (Tumour,
Lymph node and Metastasis) staging system [16].
Socioeconomic status was categorized according to
New Zealand Deprivation Index 2006 (NZDep06) [17].
NZDep06 measures socioeconomic status based on area
of residence and assigns a deprivation score on a scale
from 1 to 10 (1-least deprived 10% of areas, 10-most
deprived 10% of areas in NZ) based on nine socioeco-
nomic parameters. Distance to treatment facility where
surgery was carried out was calculated based on patients’
residential address and was categorized in to four
categories; 0-10km, 10-50km, 50-100km and >100km. A
comorbidity score for each woman was calculated using
Charlson Comorbidity Index [18], based on existing
comorbidities at the time of diagnosis of breast cancer.
Comorbidity score was categorized into 0 or ≥1.
Use of adjuvant therapy
Chemotherapy
Chemotherapy eligibility was considered only for women
younger than 70 years. Of the women considered to be eli-
gible for chemotherapy (N = 1212), women who received
either adjuvant or neo-adjuvant chemotherapy were con-
sidered to have received chemotherapy. For oestrogen
(ER) and progesterone (PR) receptor negative cancers, a
maximum tumour diameter of ≥10mm (n = 276, 22.8%)
was considered as the threshold for chemotherapy (Fig. 1).
For ER and/or PR positive tumours, defining a threshold
for chemotherapy was complicated as this decision in
most situations was based on multiple factors including
lymph node involvement, tumour grade, lympho-vascular
invasion, human epidermal growth factor receptor – type
2 (HER-2) status, and more recently, with Ki-67 and
Fig. 1 Flow diagram demonstrating the eligibility criteria and
number of women who have received chemotherapy
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tumour genotyping [19]. For ER and/or PR positive or un-
known tumours, we considered ≥20mm maximum
tumour diameter as the threshold for chemotherapy
(n = 936, 77.2%) [13, 14]. We also performed a separ-
ate analysis with a different threshold for ER and/or
PR positive cancers. For this analysis, women were
considered eligible only if one or more of lymph node
positivity, tumour grade ≥2 or lympho-vascular inva-
sion were present, in addition to a maximum tumour
diameter of ≥20mm.
Radiotherapy
Women who were deemed to be eligible for radiotherapy
(n = 1708) were identified based on following criteria
(Fig. 2). All women undergoing breast conserving surgery
without a completion mastectomy (n = 1354, 79.3%) were
considered eligible, and for women undergoing a mast-
ectomy, if the maximum tumour diameter was ≥50mm
or if ≥4 lymph nodes were positive for tumour metasta-
sis (n = 354, 20.7%) were considered eligible [13, 14].
Data analysis
Data were analysed using SPSS (Version 22) [20]. Chi
squared tests (χ2) for trend or Wilcoxson rank test were
used to test differences in use of chemotherapy and
radiotherapy among groups categorized by age, ethnicity,
stage, mode of diagnosis and year of diagnosis. Multivar-
iable logistic regression was used to derive relative odds
(odds ratios) of Maori women receiving chemotherapy
or radiotherapy compared with NZ European ethnicity
adjusted for other factors. Variables were retained in
multivariable models if p values were less than, or equal
to the conventional 5% level, or if they were considered
to be of significant clinical or population health import-
ance. Possible interactions between covariates included
in multivariate models were not studied.
Ethnic comparisons were performed between NZ
European (n = 2303, 80.9%) and Maori (n = 429, 15.1%)
populations. Pacific (n = 53, 1.9%) and Asian (n = 63,
2.2%) populations were excluded from comparisons due
to small sample size.
Logistic regression analyses were performed including
only the patients with complete data for all variables of
interest. Patients with missing data were excluded from
regression models as the missing numbers were rela-
tively small (<5%), except for HER-2 status (missing data
23.7%). Regression analyses for chemotherapy was per-
formed twice; firstly, including missing HER-2 status as
a separate category and secondly, excluding cases with
missing HER-2 status data. Odds ratios and p values
between the two models were found to be almost identi-
cal. The model with missing data as a separate category
is shown in this report. Imputation of missing values
was not undertaken due to the similarity of these results.
Results
Use of chemotherapy
Of women deemed eligible for chemotherapy, 836 (69%)
women had received chemotherapy. No significant
differences in rates of chemotherapy use were observed
between Māori and NZ European women (68.3% vs.
68.7%, p = 0.916). Chemotherapy use was significantly
higher in women of younger age groups (p < 0.001), zero
comorbidity score (p < 0.001), surgically treated in pri-
vate hospitals (p = 0.002) and non-screen detected can-
cer (p = 0.033) (Table 1). Increasing socioeconomic
deprivation tended to be associated with a lower use of
chemotherapy, although this was not statistically signifi-
cant (p = 0.402). As expected, chemotherapy use was
higher for cancers which were associated with adverse
prognostic characteristics, which included ≥5cm in diam-
eter, positive lymph node status, higher grade, lympho-
vascular invasion (LVI) and HER-2 positivity. Trends in
use of chemotherapy by tumour characteristics were
observed to be similar for Māori and NZ European
women. Among these women deemed eligible for
chemotherapy, no significant differences in the distri-
bution of tumour biological characteristics between
Maori and NZ European women were observed (Data
not shown).
Multivariate analysis of factors associated with chemo-
therapy use is shown in Table 2. Age, comorbidity score
and adverse tumour characteristics remained significant
while socio-demographic factors and surgical hospital
type were not significant.
An additional analysis was performed with a different
chemotherapy threshold for ER and/or PR positive can-
cers, considering these cancers as eligible for chemother-
apy only if the cancer had one or more of lymph node
positivity, lympho-vascular invasion or tumour grade ≥2
in addition to a maximum tumour diameter of ≥20mm.
This analysis yielded results much similar to the analysis
in Table 1 (data not shown). According to new criteria,
Fig. 2 Flow diagram demonstrating the eligibility criteria and
number of women who have received radiotherapy
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Table 1 Socio-demographic and tumour characteristics associated with use of adjuvant chemotherapya
Use of chemotherapy
Characteristic Total population (N = 1212) Total chemotherapy (N = 1212) NZ European (N = 924) Māori (N = 218)
n (%) n (%)b p n (%)b n (%)b
Overall 1212 (100) 836 (69.0) 635 (68.7) 149 (68.3)
Age (yrs.) <0.001
< 40 100 (8.3) 90 (90.0) 58 (89.2) 18 (90.0)
40-49 338 (27.9) 276 (81.7) 200 (81.3) 56 (81.2)
50-59 434 (35.8) 309 (71.2) 245 (72.5) 53 (68.8)
60-69 340 (28.1) 161 (47.4) 132 (48.0) 22 (42.3)
Deprivation 0.402
Dep 1-2 139 (11.5) 100 (71.9) 88 (71.5) 8 (80.0)
Dep 3-4 126 (10.4) 89 (70.6) 72 (70.6) 12 (75.0)
Dep 5-6 313 (25.8) 216 (69.0) 174 (67.7) 29 (70.7)
Dep 7-8 315 (26.0) 213 (67.6) 160 (67.8) 39 (61.9)
Dep 9-10 319 (26.3) 218 (68.3) 141 (68.4) 61 (69.3)
Surgical hospital type 0.002
Private 406 (33.5) 303 (74.6) 271 (74.0) 21 (80.8)
Public 806 (66.5) 533 (66.1) 364 (65.2) 128 (66.7)
Diagnostic type 0.033
Screen detected 407 (33.6) 235 (57.7) 195 (57.9) 30 (57.7)
Non-screen detected 805 (66.4) 601 (74.7) 440 (75.0) 119 (71.7)
Charlson score <0.001
0 1056 (87.1) 754 (71.4) 582 (70.5) 124 (71.7)
1+ 156 (12.9) 82 (52.6) 53 (53.5) 25 (55.6)
Diagnosis year 0.003
1999-2002 269 (22.2) 201 (74.7) 160 (73.7) 31 (79.5)
2003-2006 374 (30.9) 267 (71.4) 216 (72.5) 38 (66.7)
2007-2009 292 (24.1) 183 (62.7) 128 (60.7) 39 (65.0)
2010-2012 277 (22.9) 185 (66.8) 131 (66.2) 41 (66.1)
Grade <0.001
Grade I 168 (13.9) 70 (41.7) 62 (43.4) 6 (33.3)
Grade II 617 (50.9) 409 (66.3) 305 (66.0) 83 (66.9)
Grade III 395 (32.6) 340 (86.1) 254 (85.8) 57 (83.8)
Missing 32 (2.6) 17 (53.1) 14 (60.9) 3 (37.5)
ER/PR status <0.001
ER &/or PR + 926 (76.4) 598 (64.6) 457 (64.3) 103 (63.6)
ER & PR - 276 (22.8) 233 (84.4) 173 (84.4) 46 (83.6)
Missing 10 (0.8) 5 (50.0) 5 (62.5) 0
T stage <0.001
T1 368 (30.4) 234 (63.6) 196 (62,6) 29 (69.0)
T2 692 (57.1) 484 (69.9) 364 (71.4) 83 (62.4)
T3 83 (6.8) 64 (77.1) 40 (74.1) 19 (82.6)
T4 62 (5.1) 50 (80.6) 31 (77.5) 18 (90.0)
Missing 7 (0.6) 4 (55.6) 4 (55.6) 0
N stage <0.001
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1168 women were found to be eligible, and of this 824
(70.5%) had received chemotherapy; 623 (70.1%) of NZ
European and 149 (70.3%) of Māori women. Multivari-
able logistic regression analysis showed trends similar to
Table 2 and, for Māori, the adjusted odds for receiving
chemotherapy was 1.25 (0.85-1.87, p = 0.258).
Use of radiotherapy
Characteristics associated with use of radiotherapy are
shown in Table 3. Overall, radiotherapy was used for 1491
(87.3%) of women deemed to be eligible for radiation
based on selection criteria. Radiotherapy use was lower in
Māori compared with NZ European women (84% vs.
87.8%, p = 0.138), but the difference was statistically not
significant. Younger age at diagnosis, lower socioeconomic
deprivation, later year of diagnosis, surgical care in a pri-
vate hospital, shorter distance from the hospital, screen
detection, undergoing BCS and adverse tumour character-
istics including higher grade, stage and positive axillary
lymph node status were significantly associated with
increased likelihoods of receiving radiotherapy.
Multivariable regression analysis of factors associated
with radiotherapy use is shown in Table 4. Māori compared
with NZ European ethnicity (OR = 0.63, 95% CI, 0.40-0.98),
older age (OR = 0.96, 95% CI 0.95-0.98), distance of over
100km from the radiation facility (OR = 0.47, 95% CI, 0.23-
0.96, higher comorbidity score (OR = 0.49, 95% CI,
0.34-0.72), mastectomy compared with BCS (OR = 0.32,
95% CI, 0.17-0.57) and non-screen compared with
screen detection (OR = 0.53, 95% CI, 0.35-0.79) were
significantly associated with lower likelihoods of receiv-
ing radiotherapy in this model.
Further analyses were performed for women undergoing
BCS and mastectomy separately (Data not shown). These
analyses confirmed that Māori were less likely to have
received radiation following mastectomy (OR = 0.54, 0.24-
1.22, p = 0.134) and BCS (OR = 0.70, 0.41-1.43, p = 0.402),
Table 1 Socio-demographic and tumour characteristics associated with use of adjuvant chemotherapya (Continued)
0 406 (33.5) 223 (54.9) 165 (54.6) 37 (50.0)
1 537 (44.3) 381 (70.9) 291 (70.0) 72 (74.2)
2+ 269 (22.2) 232 (86.2) 179 (86.9) 40 (85.1)
LVI <0.001
Negative 783 (64.6) 484 (61.8) 362 (61.0) 88 (62.0)
Positive 429 (35.4) 352 (82.1) 273 (82.5) 61 (80.3)
HER-2 <0.001
Negative 658 (54.3) 414 (62.9) 314 (63.2) 79 (60.8)
Equivocal 48 (4.0) 25 (52.1) 17 (48.6) 6 (66.7)
Positive 219 (18.1) 188 (85.8) 134 (86.5) 37 (80.4)
Missing 287 (23.7) 209 (72.8) 170 (71.7) 27 (81.8)
aOnly ER and PR negative cancers ≥10mm and ER and/or PR positive cancers ≥20mm in women <70 years are included
bProportion of women who had received chemotherapy in each category
Table 2 Multivariable logistic regression analysis for factors
associated with use of adjuvant chemotherapy (Number of
patients included in the regression analysis = 1064 [87.8%])
Characteristic OR 95% CI p
Māori ethnicitya 1.02 0.90-1.14 0.934
Ageb 0.92 0.91-0.94 <0.001
Year of diagnosisc 0.94 0.88-1.02 0.122
ER and/or PR positived 0.34 0.21-0.57 <0.001
Deprivatione 0.98 0.87-1.11 0.733
Charlson score 0.34 0.17-0.60 <0.001
Surgery in public vs. private 1.07 0.77-1.49 0.688
T stagef
T 2 1.58 1.12-2.23 0.009
T 3 1.47 0.65-2.49 0.486
T 4 1.23 0.41-3.41 0.876
N stageg
N 1 2.49 1.71-3.64 <0.001
N 2+ 8.41 4.37-16.2 <0.001
Gradeh
Grade II 2.41 1.58-3.70 <0.001
Grade III 4.79 2.87-7.99 <0.001
LVIi 1.78 1.22-2.61 <0.001
HER-2j
HER-2 Equivocal 0.55 0.26-1.15 0.116
HER-2 Positive 2.02 1.23-3.33 0.006
HER-2 Unknown 1.36 0.83-2.24 0.548
aMaori compared with NZ European ethnicity
bAge as a continuous variable
cYear of diagnosis as a continuous variable
dER and/or PR positive compared with ER & PR negative
eDeprivation as a continuous variable
fReference category T1 stage
gReference category N0 stage
hReference category Grade I
iReference category LVI negative
jReference category HER-2 negative
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Table 3 Socio-demographic and tumour characteristics associated with use of adjuvant radiotherapy
Use of radiotherapy
Characteristic Total population (N = 1708) Total (N = 1708) NZ European (N = 1418) Māori (N = 225)
n (%) n (%)a p n (%)a n (%)a
Overall 1708 1491 (87.3) 1255 (87.8) 189 (84.0)
Age (yrs.) <0.001
< 40 79 (4.6) 76 (96.2) 50 (96.2) 16 (94.1)
40-49 328 (19.2) 302 (92.1) 231 (93.9) 52 (86.7)
50-59 499 (29.2) 456 (91.4) 377 (92.0) 66 (90.4)
60-69 471 (27.6) 417 (88.5) 361 (90.5) 45 (75.0)
70-79 218 (12.8) 172 (78.9) 161 (78.9) 8 (72.7)
80+ 113 (6.6) 68 (60.2) 65 (60.7) 2 (50.0)
Diagnosis year 0.003
1999-2002 357 (20.9) 296 (82.9) 255 (83.9) 30 (76.9)
2003-2006 506 (29.6) 443 (87.5) 396 (88.0) 37 (86.0)
2007-2009 406 (23.8) 354 (87.2) 284 (87.4) 50 (84.7)
2010-2012 439 (25.7) 398 (90.7) 310 (91.4) 72 (85.7)
Deprivation 0.006
Dep 1-2 178 (10.4) 167 (93.8) 156 (94.0) 5 (83.3)
Dep 3-4 186 (10.9) 163 (87.6) 140 (87.5) 17 (94.4)
Dep 5-6 414 (24.2) 364 (87.9) 318 (88.1) 37 (90.2)
Dep 7-8 491 (28.7) 423 (86.2) 356 (87.9) 54 (77.1)
Dep 9-10 439 (25.7) 374 (85.2) 275 (84.4) 76 (84.4)
Distance 0.005
< 10km 546 (32.0) 489 (89.6) 409 (90.5) 54 (85.7)
10-50km 660 (38.6) 579 (89.1) 488 (88.1) 70 (85.6)
50-100km 428 (25.1) 364 (85.0) 310 (85.4) 49 (83.1)
> 100km 74 (4.3) 59 (79.7) 38 (79.2) 16 (76.2)
Missing
Diagnostic type <0.001
Screen detected 750 (43.9) 698 (93.1) 602 (93.3) 76 (90.5)
Symptomatic 958 (56.1) 793 (82.8) 643 (83.2) 113 (80.1)
Hospital type <0.001
Private 535 (31.3) 488 (91.2) 453 (91.5) 25 (86.2)
Public 1173 (68.7) 1003 (85.5) 792 (85.8) 164 (83.7)
Surgery type <0.001
BCS 1354 (79.3) 1213 (89.6) 1031 (89.7) 143 (88.8)
Mastectomy 354 (20.7) 278 (78.5) 214 (79.9) 46 (71.9)
Grade 0.493
Grade I 441 (25.8) 381 (86.4) 341 (87.0) 27 (79.4)
Grade II 865 (50.6) 754 (87.2) 626 (88.0) 102 (82.9)
Grade III 371 (21.7) 331 (89.2) 257 (89.2) 56 (87.5)
Unknown 31 (1.8) 25 (80.6) 21 (77.8) 4 (100)
T stage <0.001
T1 1020 (59.7) 915 (90.1) 790 (90.1) 98 (89.9)
T2 518 (30.3) 437 (84.4) 356 (85.8) 57 (76.0)
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although these differences were not statistically significant.
Significantly lower likelihoods of receiving radiation fol-
lowing both BCS and mastectomy were seen for women
of older age (OR = 0.94, 95% CI 0.92-0.96 and OR = 0.95,
95% CI 0.93-0.97 respectively), non-screen compared with
screen detected (OR = 0.43, 95% CI, 0.31-0.55 and
OR = 0.72, 95% CI 0.31-1.70, respectively) and for
women with comorbidity (OR = 0.32, 95% CI 0.21-
0.43 and OR = 0.28, 95% CI 0.16-0.52, respectively).
Discussion
This study has shown that use of adjuvant radiotherapy
has been significantly lower in Indigenous Māori com-
pared with NZ European women with breast cancer,
based on accepted practice guidelines over the study
period [13, 14]. No significant difference in the use of
chemotherapy was observed between Māori and NZ
European women. Further, significantly lower use of
radiotherapy was seen among rural compared with
urban dwelling women and non-screen compared with
screen detected women. Overall, the use of radiation
was lower than expected based on guidelines [13, 14],
and was substantially worse for post-mastectomy radi-
ation (78.5%) than for radiation following BCS (89.6%).
Although the use of radiotherapy seems to have in-
creased over time, a substantial proportion of potentially
eligible women (9%) have not received radiation even
during 2010-2012.
Lower use of adjuvant chemotherapy in minority eth-
nic cancer patients are well documented in the USA,
and include lower use of chemotherapy for breast, colon
and lung among many other cancers [21, 22]. Not only
that these patients have experienced lower use of
adjuvant chemotherapy, but on many occasions were
subjected to longer delays and use of chemotherapy
regimens not in keeping with recommended guidelines
[23–25]. Similarly, lower use and longer delays for adju-
vant chemotherapy for bowel cancer in Māori compared
with non-Māori patients have supported the existence of
similar ethnic disparities in New Zealand [7]. Despite
that, we did not observe a significant difference between
Māori and NZ European women in the use of adjuvant
chemotherapy for breast cancer, either in univariate or
multivariate models. However, a previous analysis based
on the WBCR found that Māori women were signifi-
cantly more likely to experience longer delays for initi-
ation of chemotherapy than for NZ European women
Table 3 Socio-demographic and tumour characteristics associated with use of adjuvant radiotherapy (Continued)
T3 100 (5.9) 79 (79.0) 54 (76.1) 20 (87.0)
T4 70 (4.1) 58 (82.9) 43 (84.3) 14 (77.8)
N stage 0.042
0 1029 (60.3) 900 (87.8) 762 (87.8) 106 (86.9)
1 363 (21.2) 321 (88.9) 266 (90.2) 45 (83.3)
2+ 316 (18.5) 266 (84.2) 215 (93.1) 36 (76.6)
Charlson score <0.001
0 1456 (85.2) 1312 (90.1) 1111 (90.7) 151 (85.8)
1+ 252 (14.8) 179 (71.0) 134 (69.4) 38 (77.6)
aProportion of women who had received radiotherapy in each category
Table 4 Multivariable logistic regression analysis for factors
associated with use of adjuvant radiotherapy (Number of
patients included in the regression analysis = 1643 [96.2%])
Characteristic OR 95% CI p
Māori ethnicitya 0.63 0.40-0.98 0.040
Ageb 0.96 0.95-0.98 <0.001
Year of diagnosisc 1.07 1.02-1.11 0.004
Deprivationd 0.92 0.79-1.06 0.232
Distancee
10-50 km 0.74 0.50-1.09 0.130
50-100 km 0.67 0.44-1.03 0.067
> 100km 0.47 0.23-0.96 0.040
Charlson scoref 0.49 0.34-0.72 <0.001
Surgery in public vs. private 0.86 0.61-1.26 0.467
Non-screen vs. screen detection 0.53 0.35-0.79 0.002
Mastectomy vs. BCS 0.32 0.17-0.57 <0.001
T stageg
T 2 0.84 0.57-1.24 0.394
T 3 1.09 0.53-2.24 0.809
T 4 1.42 0.66-3.07 0.366
N stageh
N 1 1.45 0.94-2.24 0.093
N 2+ 2.66 1.38-5.10 0.003
aMaori compared with NZ European ethnicity
bAge as a continuous variable
cYear of diagnosis as a continuous variable
dDeprivation as a continuous variable
eReference category Distance <10km
fReference category Charlson score = 0
gReference category T1 stage
hReference category N0 stage
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[9]. Further, we have not analysed the use of recom-
mended regimens of chemotherapy or rates of comple-
tion of chemotherapy in the present study. Hence,
although we have not observed an ethnic disparity in
overall adjuvant chemotherapy use, further research is
needed to investigate possible disparities in other areas
of chemotherapy use including rates of completion and
use of recommended regimens.
Overall, use of radiotherapy fell short of recommended
guidelines, and was significantly lower for Māori com-
pared with NZ European women [13, 14]. Similar inequi-
ties in the use of adjuvant radiotherapy for breast cancer
have been reported from the USA, between minority
African American and White American women [21, 26].
It appears that socio-demographically disadvantaged
women (i.e. Māori, rural residence and high socioeco-
nomic deprivation) had higher likelihoods of not receiving
adjuvant radiation, while no such differences were ob-
served for chemotherapy. Differences in difficulty in
accessing radiotherapy in comparison to chemotherapy
might have at least partially been responsible for this dif-
ference. Adjuvant radiation for the study population was
provided through the central radiation facility at the
tertiary hospital in Hamilton. As radiotherapy requires at-
tending a radiation facility five days a week over a period,
ranging from four to six weeks, for women residing in re-
mote and rural areas this would have posed a significant
barrier due to difficulties with time and cost of travel.
Many rural women with breast cancers suitable for BCS
opting for mastectomy due to similar reasons is well docu-
mented in the literature [27]. Women of low socioeco-
nomic groups also face similar barriers due to difficulties
with transport, taking time off work or due to lack of
support to care for dependants, resulting in lower use of
radiotherapy [28]. Higher proportions of Māori live in
rural areas and are more likely to be socioeconomically
deprived contributing to lower radiotherapy use in Māori.
However, Maori ethnicity appears to be an independent
risk factor for lower use of radiotherapy as observed in the
multivariate model.
Women with screen detected cancer were significantly
more likely to have received radiotherapy compared to
women with non-screen detected women, a common
pattern following both mastectomy and BCS. Diagnostic
and treatment indicators for women diagnosed through
BSA programme are routinely measured and perform-
ance of each screening provider is regularly audited
against pre-established criteria. For instance, at least 95%
of women diagnosed through BSA are expected to have
received radiotherapy following BCS for invasive cancer
[29]. If a provider fails to achieve these targets corrective
measures are initiated through a feedback process. How-
ever, similar quality measures or audit processes were
non-existent for symptomatically detected cancer. This
provides a likely explanation for higher radiotherapy
rates seen for screen detected cancer, despite these can-
cers generally carrying a lower risk of local recurrence
compared with non-screen detected cancer. This obser-
vation highlights a failure of the healthcare system,
where women with lower risk cancers have likely been
prioritized to receive treatment over women with higher
risk cancers. Such inequities in care are likely to further
exacerbate inequities in breast cancer outcomes seen
between Māori and NZ European women, especially
since Māori women have a significantly lower screening
coverage [29], and as a result, a lower proportion of
screen detected cancer.
Main strengths of this study include the complete-
ness of the population based sample which included
more than 98% of all breast cancers diagnosed in the
Waikato region over the study period and compre-
hensive nature of the data included [15]. As the
population distributions, provision of breast screening
and treatment services in the Waikato region are
much similar to rest of New Zealand, and hence find-
ings from this study are likely to be representative of
the whole country [12, 29, 30].
However, there were several limitations. First, although
we observed differences in adjuvant therapy among
some groups of interest and several associations, we
could not ascertain exact causes for non-use (i.e. not re-
ferred, not seen by an oncologist or patient declined)
due to non-availability of this information from the
WBCR. Selection of patients for chemotherapy is com-
plicated and is based on multiple factors including age,
tumour size, grade, ER/PR, lymph node status and
lympho-vascular invasion. As a result, criteria used for
eligibility for chemotherapy were not absolute, especially
for women with ER/PR positive cancers. This is a likely
reason for the much lower use of chemotherapy use in
the selected population (69%) compared with radiother-
apy use (87.3%), for which the eligibility criteria were
less complicated. Further, no major differences in NZ
treatment guidelines for the use of breast cancer adju-
vant therapy was observed during the study period [13].
Hence, any impact of such changes in guidelines are un-
likely to have influenced the study findings. As we did not
observe major differences in distribution of tumour bio-
logical characteristics between Māori and NZ European
women that might have influenced the use of chemother-
apy, such factors are unlikely to have influenced patient
selection for chemotherapy in a differential manner.
Conclusion
In conclusion, we observed significantly lower use of
radiotherapy for Māori and women living at a distance
of >100km from the hospital, although similar disparities
were not observed for chemotherapy. Difficulties in
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accessing radiotherapy appeared to be a major contribu-
tor towards differences observed by ethnicity, geographic
location and socioeconomic status. Failures of the
healthcare system to providing equitable care were also
evident by the discrepancy in radiotherapy seen between
screen and non-screen detected women. Increasing
availability and improving access for breast cancer adju-
vant therapy for women who are at a higher risk of not
receiving adjuvant therapy due to ethnicity, geography
or socioeconomic position need to be recognized as
priorities, which may help minimize breast cancer
outcome inequities.
Abbreviations
BCS: Breast conserving surgery; BSA: BreastScreen Aotearoa; ER: Oestrogen
receptor; HER 2: Human epidermal growth factor receptor type 2; NZ: New
Zealand; NZDep06: New Zealand deprivation index 2006; OR: Odds ratio;





We acknowledge funding support received from the Waikato Breast Cancer
Trust, the Cancer Society of New Zealand, the New Zealand Breast Cancer
Foundation, the Lion Foundation, Grassroots Trust and the WEL energy trust
for the WBCR and for additional data collection included for this study.
Availability of data and materials
Data will be made available on request by contacting the corresponding
author.
Authors’ contributions
SS developed the concept, designed the study, developed the methodology,
collected data and performed the analysis. SS wrote up the initial version of the
manuscript and IC, NS and RL provided comments. All authors contributed to
the final version of the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical approval for this study was obtained from the New Zealand Northern
‘A’ Ethics Committee (Ref. No. 12/NTA/42). Individual patient consent was
not required due to the observational nature of the study.
Author details
1Waikato Clinical School, University of Auckland, Hamilton, New Zealand.
2Māori Health Services, Waikato District Health Board, Hamilton, New
Zealand. 3Department of Surgery, University of Colombo, Colombo, Sri Lanka.
Received: 25 September 2015 Accepted: 17 January 2017
References
1. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment,
and survival by race and ethnicity. Arch Intern Med. 2003;163(1):49–56.
2. O'Malley CD, Le GM, Glaser SL, Shema SJ, West DW. Socioeconomic status
and breast carcinoma survival in four racial/ethnic groups: a population-
based study. Cancer. 2003;97(5):1303–11.
3. Valery PC, Coory M, Stirling J, Green AC. Cancer diagnosis, treatment, and
survival in Indigenous and non-Indigenous Australians: a matched cohort
study. Lancet. 2006;367(9525):1842–8.
4. Bramley D, Hebert P, Jackson R, Chassin M. Indigenous disparities in disease-
specific mortality, a cross-country comparison: New Zealand, Australia,
Canada, and the United States. N Z Med J. 2004;117(1207).
5. Freedman RA, He Y, Winer EP, Keating NL. Racial/Ethnic differences in
receipt of timely adjuvant therapy for older women with breast cancer: are
delays influenced by the hospitals where patients obtain surgical care?
Health Serv Res. 2013;48(5):1669–83.
6. Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL.
The association of race/ethnicity, insurance status, and socioeconomic
factors with breast cancer care. Cancer. 2011;117(1):180–9.
7. Hill S, Sarfati D, Blakely T, Robson B, Purdie G, Dennett E, Cormack D, Dew K,
Ayanian JZ, Kawachi I. Ethnicity and management of colon cancer in New
Zealand: do indigenous patients get a worse deal? Cancer. 2010;116(13):
3205–14.
8. Seneviratne S, Campbell I, Scott N, Coles C, Lawrenson R. Treatment delay
for Māori women with breast cancer in New Zealand. Ethn Health. 2015;
20(2):178–93.
9. Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Round G,
Lawrenson R. Ethnic differences in timely adjuvant chemotherapy and
radiation therapy for breast cancer in New Zealand: a cohort study.
BMC Cancer. 2014;14(1):839.
10. Lawrenson R, Seneviratne S, Scott N, Peni T, Brown C, Campbell I. Breast
cancer inequities between Māori and non‐Māori women in Aotearoa/New
Zealand. Eur J Cancer Care. 2016;25(2):225–30.
11. Robson B, Purdie G, Cormack D: Unequal Impact II: Māori and Non-Māori
Cancer Statistics by Deprivation and Rural-Urban Status 2002-2006. In.
Wellington: Ministry of Health; 2010
12. 2013 Census Data [http://www.stats.govt.nz/Census/2013-census/data-
tables/tables-about-a-place.aspx?request_value=24417&tabname=].
Accessed 10 Nov 2015.
13. New Zealand Guidelines Group: Management of early breast cancer - evidence
based best practice guideline. In. Wellington: Ministry of Health; 2009
14. National Breast and Ovarian Cancer Centre: Clinical Practise Guidelines for
the Management of Early Breast Cancer. In., 2nd edn. Australia: National
Health and Medical Research Council (NHMRC), Australia; 2001.
15. Seneviratne S, Campbell I, Scott N, Shirley R, Peni T, Lawrenson R. Accuracy
and completeness of the New Zealand Cancer Registry for staging of
invasive breast cancer. Cancer Epidemiol. 2014;38(5):638–44.
16. American Joint Committee on Cancer: AJCC Cancer Staging Manual. In., 7th
edn. New York: Springer-Verlag; 2010.
17. NZDep2006: Index of Deprivation. In.: Department of Public Health,
University of Otago, Wellington. Ministry of Health; 2007.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40(5):373–83.
19. Goldhirsch A, Ingle JN, Gelber R, Coates A, Thürlimann B, Senn H-J.
Thresholds for therapies: highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann Oncol.
2009;20(8):1319–29.
20. IBM Corp: IBM SPSS Statistics for Windows, Version 22.0. In. Armonk, NY; 2013.
21. Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J,
Guth AA. Missed opportunities: racial disparities in adjuvant breast cancer
treatment. J Clin Oncol. 2006;24(9):1357–62.
22. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD,
O'Connor LC, West DW, Allen ME, Wolf RE, et al. Use of adjuvant
chemotherapy and radiation therapy for colorectal cancer in a population-
based cohort. J Clin Oncol. 2003;21(7):1293–300.
23. Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford
J, Dale DC, Lyman GH. Social and racial differences in selection of
breast cancer adjuvant chemotherapy regimens. J Clin Oncol. 2007;
25(18):2522–7.
24. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in
the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast
Cancer Res Treat. 2003;81(1):21–31.
25. Smith K, Wray L, Klein-Cabral M, Schuchter L, Fox K, Glick J, DeMichele A. Ethnic
disparities in adjuvant chemotherapy for breast cancer are not caused by
excess toxicity in black patients. Clin Breast Cancer. 2005;6(3):260–6.
26. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic
differences in breast cancer survival: how much is explained by screening,
tumor severity, biology, treatment, comorbidities, and demographics?
Cancer. 2008;112(1):171–80.
Seneviratne et al. BMC Health Services Research  (2017) 17:64 Page 9 of 10
27. Schroen AT, Brenin DR, Kelly MD, Knaus WA, Slingluff CL. Impact of patient
distance to radiation therapy on mastectomy use in early-stage breast
cancer patients. J Clin Oncol. 2005;23(28):7074–80.
28. Gilligan MA, Kneusel RT, Hoffmann RG, Greer AL, Nattinger AB. Persistent
differences in sociodemographic determinants of breast conserving
treatment despite overall increased adoption. Med Care. 2002;40(3):181–9.
29. Page A, Morrell S, Taylor R: BreastScreen Aotearoa: Independent Monitoring
Report, Screening and assessment report of women attending BSA. In.
Wellington: National Screening Unit, Ministry of Health; 2014
30. Regional Cancer Networks [http://www.health.govt.nz/our-work/diseases-
and-conditions/cancer-programme/regional-cancer-networks]. Accessed 10
Dec 2015.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Seneviratne et al. BMC Health Services Research  (2017) 17:64 Page 10 of 10
